Profusa, Inc. (PFSA)
Nasdaq · Healthcare · Medical Devices
$1.75+3.55%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1M
- 52-week range
- $1.58 – $3,000.00
- 52-week change
- −99.94%
- EPS (trailing)
- $897.26
Fiscal year to Dec 2025
- Net income
- −$35.8M
- Diluted EPS
- −$107.01
- Free cash flow
- −$16.3M
From the company’s annual report on SEC EDGAR.
About Profusa, Inc.
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Headquarters: Berkeley, United States · profusa.com